Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE), invites to a teleconference for investors, analysts and media on Thursday, February 24, 2022, at 10.00 a.m. CET. Xbrane will publish the company’s Year-end report 2021, on Thursday, February 24, 2022, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the Year-end report 2021, followed by a Q&A session. The presentation will be in English. To attend, please follow the link or dial-in at one of the numbers below:

Web link:
https://edge.media-server.com/mmc/p/43thqez6

Confirmation Code: 688 50 49
Standard international: +44 (0) 2071 928 338
UK (Local): +44 (0) 844 481 97 52
UK (Tollfree): +44 (0) 800 279 66 19
Sweden (Local): +46 (0) 856 618 467
Sweden (TollFree): +46 (0) 20 012 51 60
US (Local): +1 646 741 31 67
US (TollFree): +1 877 870 91 35

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting €28 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

Attachments

Invitation to presentation of Xbrane Biopharma’s Year-end report 2021 on February 24, 2022.

© Modular Finance, source Nordic Press Releases